<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375427</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446EIT14</org_study_id>
    <nct_id>NCT00375427</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions</brief_title>
  <official_title>A Prospective, Randomized, Multi-center Comparative 2-arm Trial of Efficacy and Safety of Zoledronic Acid (Every 3-months vs. Every 4 Weeks) Beyond Approximately 1 Year of Treatment With Zoledronic Acid in Patients With Bone Lesions From Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the clinical benefit of two different dosing
      schedules of zoledronic acid in patients with metastatic bone lesions from breast cancer who
      have already been treated with zoledronic acid for about one year.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual Overall Skeletal Morbidity Rate (SMR)</measure>
    <time_frame>12 months</time_frame>
    <description>The SMR was computed by summing all Skeletal Related Event(s) (SREs)which occurred during the observation period and dividing it by the ratio &quot;days of observation period / 365.25&quot;, for each participant. SRE was defined as: pathologic bone fracture, spinal cord compression, surgery to bone both curative and prophylactic, radiation therapy to bone, or hypercalcemia of malignancy.
SMR (years) = 365.25 x SMR(days) where SMR (days) = total number of SREs / total SRE risk period (days). Risk period for SMR was computed as the days from randomization date to the date of last visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Skeletal Related Event(s) (SREs)</measure>
    <time_frame>12 month</time_frame>
    <description>Skeletal Related Events (SREs) are defined as a:
pathologic bone fracture such as non-vertebral and vertebral compression fractures
spinal cord compression identified by positive diagnosis documented by X-ray evidence
surgery to bone both curative and prophylactic
radiation therapy to bone including palliative, therapeutic or prophylactic
hypercalcemia of malignancy, defined as a corrected serum calcium &gt; 12 mg/dl (3.00 mmol/l) or a lower level of hypercalcemia which is symptomatic and which requires active treatment other than rehydration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Incidence of Any Skeletal Related Events (SREs)</measure>
    <time_frame>12 months</time_frame>
    <description>Skeletal Related Events (SREs) are defined as a:
pathologic bone fracture such as non-vertebral and vertebral
spinal cord compression identified by X-rays evidence
surgery to bone both curative and prophylactic
radiation therapy to bone including palliative, therapeutic or prophylactic
hypercalcemia of malignancy, defined as a corrected serum calcium &gt; 12 mg/dl (3.00 mmol/l) or a lower level of hypercalcemia which is symptomatic and which requires active treatment other than rehydration. Annual incidence for each SRE was computed in the same way as annual overall SMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to First Skeletal Related Event(s) (SRE)</measure>
    <time_frame>12 month</time_frame>
    <description>Median Time to first skeletal related event (SRE) is defined as the time from randomization to the date of first occurrence of any SRE which includes at least one of the following: radiation therapy to bone, pathologic bone fracture, spinal cord compression, surgery to bone, and hypercalcemia of malignancy (HCM). Due to the few numbers of SRE, Kaplan-Meier estimate never reaches a failure probability &gt;=25%; so median time, 25th and 75th percentiles are not determined.For this reason only the estimated percentage of patient SRE free are reported at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Skeletal Related Event (SRE) Free</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants SRE free is defined as the Kaplan-Meier estimate of participants free of any Skeletal Related Events(SRE) at each time point.
Skeletal Related Events (SREs) are:
pathologic bone fracture; non-vertebral and vertebral
spinal cord compression identified by X-rays
surgery to bone both curative and prophylactic
radiation therapy to bone (palliative, therapeutic or prophylactic)
hypercalcemia of malignancy, defined as a corrected serum calcium &gt; 12 mg/dl (3.00 mmol/l) or a lower level which is symptomatic and requires treatment other than rehydration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Bone Pain Score According to the Brief Pain Inventory (BPI) Questionnaire</measure>
    <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
    <description>Bone pain was assessed by means of a pain score obtained using the Brief Pain Inventory (BPI) questionnaire. The BPI can produce three pain scores: worst pain, a composite pain score, and a pain interference score. The composite pain score, which is the average of questions 3, 4, 5 and 6 of the questionnaire was used in this study. Pain was rated on a scale of 0 (no pain) to 10 (pain as bad as you can imagine). The outcome is given as the median score for participants at baseline, and 3, 6, 9 and 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pain According to Verbal Rating Scale (VRS) Based on Median Score Value</measure>
    <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
    <description>Pain intensity at rest and on movement is rated by the patient by means of a validated 6-point Verbal Rating Scale (VRS) and refers to the pain which occurred during the last week before the assessment. Median score value is the median of all the observed scores (none=0, very mild=1, mild=2, moderate=3, severe=5 and very severe=6) at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use Of Analgesic Medications According to the Analgesic Score Scale</measure>
    <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
    <description>The analgesic score used for this study is modified from the Radiation Therapy Oncology Group (RTOG) analgesic score scale. The scale represents type of medication administered from 0 to 4 where:
0 = None
= Minor analgesics (aspirin, NSAID, acetaminophen, propoxyphene, etc.)
= Tranquilisers, antidepressants, muscle relaxants, and steroids
= Mild narcotics (oxycodone, meperidine, codeine, etc.)
= Strong narcotics (morphine, hydromorphone, etc.) The outcome is given a the median score for the participants at Baseline and 3, 6, 9 and 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the Eastern Cooperative Oncology Group (ECOG) Performance Score</measure>
    <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
    <description>ECOG Performance Score has 4 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. Outcome is given as median score for participants at Baseline and 3, 6 , 9 and 12 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Breast Cancer With Bone Metastasis</condition>
  <arm_group>
    <arm_group_label>Every 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized patients will receive a maximum of 4 infusions in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Patients randomized to this group will receive up to 12 infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.</description>
    <arm_group_label>Every 3 months</arm_group_label>
    <arm_group_label>Every 4 weeks</arm_group_label>
    <other_name>ZOL446</other_name>
    <other_name>Zometa®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Female patients ≥ 18 years of age.

          -  Written informed consent given.

          -  Histologically confirmed Stage IV breast cancer with at least one bone metastasis
             radiologically confirmed.

          -  Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no
             more than 15 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2 .

          -  Life expectancy ≥ 1 year.

        Exclusion criteria:

          -  More than 3 months since last infusion of Zoledronic Acid (Zometa®).

          -  Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior
             to study entry.

          -  Serum creatinine &gt; 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula)
             creatinine clearance (CLCr) &lt; 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72
             x serum creatinine (mg/dL)])x 0.85

          -  Corrected (adjusted for serum albumin) serum calcium &lt; 8 mg/dl (2 mmol/L) or &gt; 12
             mg/dL ( 3.0 mmol/L).

          -  Current active dental problem including infection of the teeth or jawbone (maxilla or
             mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of
             osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after
             dental procedures.

          -  Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants).

          -  Pregnant patients (with a positive pregnancy test prior to study entry) or lactating
             patients. Women of childbearing potential not using effective methods of birth control
             (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge,
             or condom with spermicide).

          -  History of non-compliance to medical regimens or potential unreliable behavior.

          -  Known sensitivity to study drug(s) or class of study drug(s).

          -  Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study

          -  Use of any other investigational agent in the last 30 days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Forlì</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2006</study_first_submitted>
  <study_first_submitted_qc>September 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2006</study_first_posted>
  <results_first_submitted>February 28, 2011</results_first_submitted>
  <results_first_submitted_qc>July 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2011</results_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Zoledronic acid</keyword>
  <keyword>Skeletal related events (SRE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total enrollment was 430; five participants were screened but not treated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid Every 3 Months</title>
          <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
        </group>
        <group group_id="P2">
          <title>Zoledronic Acid Every 4 Weeks</title>
          <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="209">Total enrollment was 430 but five patients were screened but not treated.</participants>
                <participants group_id="P2" count="216"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid Every 3 Months</title>
          <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
        </group>
        <group group_id="B2">
          <title>Zoledronic Acid Every 4 Weeks</title>
          <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="209"/>
            <count group_id="B2" value="216"/>
            <count group_id="B3" value="425"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="11.9"/>
                    <measurement group_id="B2" value="59.8" spread="11.8"/>
                    <measurement group_id="B3" value="60.1" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual Overall Skeletal Morbidity Rate (SMR)</title>
        <description>The SMR was computed by summing all Skeletal Related Event(s) (SREs)which occurred during the observation period and dividing it by the ratio “days of observation period / 365.25”, for each participant. SRE was defined as: pathologic bone fracture, spinal cord compression, surgery to bone both curative and prophylactic, radiation therapy to bone, or hypercalcemia of malignancy.
SMR (years) = 365.25 x SMR(days) where SMR (days) = total number of SREs / total SRE risk period (days). Risk period for SMR was computed as the days from randomization date to the date of last visit.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every 3 Months</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid Every 4 Weeks</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Overall Skeletal Morbidity Rate (SMR)</title>
          <description>The SMR was computed by summing all Skeletal Related Event(s) (SREs)which occurred during the observation period and dividing it by the ratio “days of observation period / 365.25”, for each participant. SRE was defined as: pathologic bone fracture, spinal cord compression, surgery to bone both curative and prophylactic, radiation therapy to bone, or hypercalcemia of malignancy.
SMR (years) = 365.25 x SMR(days) where SMR (days) = total number of SREs / total SRE risk period (days). Risk period for SMR was computed as the days from randomization date to the date of last visit.</description>
          <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
          <units>Number of Skeletal Events per Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.81"/>
                    <measurement group_id="O2" value="0.22" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Skeletal Related Event(s) (SREs)</title>
        <description>Skeletal Related Events (SREs) are defined as a:
pathologic bone fracture such as non-vertebral and vertebral compression fractures
spinal cord compression identified by positive diagnosis documented by X-ray evidence
surgery to bone both curative and prophylactic
radiation therapy to bone including palliative, therapeutic or prophylactic
hypercalcemia of malignancy, defined as a corrected serum calcium &gt; 12 mg/dl (3.00 mmol/l) or a lower level of hypercalcemia which is symptomatic and which requires active treatment other than rehydration.</description>
        <time_frame>12 month</time_frame>
        <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every 3 Months</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid Every 4 Weeks</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Skeletal Related Event(s) (SREs)</title>
          <description>Skeletal Related Events (SREs) are defined as a:
pathologic bone fracture such as non-vertebral and vertebral compression fractures
spinal cord compression identified by positive diagnosis documented by X-ray evidence
surgery to bone both curative and prophylactic
radiation therapy to bone including palliative, therapeutic or prophylactic
hypercalcemia of malignancy, defined as a corrected serum calcium &gt; 12 mg/dl (3.00 mmol/l) or a lower level of hypercalcemia which is symptomatic and which requires active treatment other than rehydration.</description>
          <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient with any SRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83"/>
                    <measurement group_id="O2" value="15.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vertebral pathological fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44"/>
                    <measurement group_id="O2" value="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non vertebral pathological fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35"/>
                    <measurement group_id="O2" value="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal cord compression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96"/>
                    <measurement group_id="O2" value="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiation to bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.53"/>
                    <measurement group_id="O2" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery to bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96"/>
                    <measurement group_id="O2" value="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercalcemia of malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48"/>
                    <measurement group_id="O2" value="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Incidence of Any Skeletal Related Events (SREs)</title>
        <description>Skeletal Related Events (SREs) are defined as a:
pathologic bone fracture such as non-vertebral and vertebral
spinal cord compression identified by X-rays evidence
surgery to bone both curative and prophylactic
radiation therapy to bone including palliative, therapeutic or prophylactic
hypercalcemia of malignancy, defined as a corrected serum calcium &gt; 12 mg/dl (3.00 mmol/l) or a lower level of hypercalcemia which is symptomatic and which requires active treatment other than rehydration. Annual incidence for each SRE was computed in the same way as annual overall SMR.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every 3 Months</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid Every 4 Weeks</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Incidence of Any Skeletal Related Events (SREs)</title>
          <description>Skeletal Related Events (SREs) are defined as a:
pathologic bone fracture such as non-vertebral and vertebral
spinal cord compression identified by X-rays evidence
surgery to bone both curative and prophylactic
radiation therapy to bone including palliative, therapeutic or prophylactic
hypercalcemia of malignancy, defined as a corrected serum calcium &gt; 12 mg/dl (3.00 mmol/l) or a lower level of hypercalcemia which is symptomatic and which requires active treatment other than rehydration. Annual incidence for each SRE was computed in the same way as annual overall SMR.</description>
          <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
          <units>Number of SRE per Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vertebral pathological fracture rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.19"/>
                    <measurement group_id="O2" value="0.02" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-vertebral pathological fracture rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.58"/>
                    <measurement group_id="O2" value="0.03" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal cord compression rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.10"/>
                    <measurement group_id="O2" value="0.00" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiation to bone rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.67"/>
                    <measurement group_id="O2" value="0.14" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery to bone rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.21"/>
                    <measurement group_id="O2" value="0.00" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercalcemia of malignancy rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.08"/>
                    <measurement group_id="O2" value="0.02" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to First Skeletal Related Event(s) (SRE)</title>
        <description>Median Time to first skeletal related event (SRE) is defined as the time from randomization to the date of first occurrence of any SRE which includes at least one of the following: radiation therapy to bone, pathologic bone fracture, spinal cord compression, surgery to bone, and hypercalcemia of malignancy (HCM). Due to the few numbers of SRE, Kaplan-Meier estimate never reaches a failure probability &gt;=25%; so median time, 25th and 75th percentiles are not determined.For this reason only the estimated percentage of patient SRE free are reported at each time point.</description>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every 3 Months</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid Every 4 Weeks</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to First Skeletal Related Event(s) (SRE)</title>
          <description>Median Time to first skeletal related event (SRE) is defined as the time from randomization to the date of first occurrence of any SRE which includes at least one of the following: radiation therapy to bone, pathologic bone fracture, spinal cord compression, surgery to bone, and hypercalcemia of malignancy (HCM). Due to the few numbers of SRE, Kaplan-Meier estimate never reaches a failure probability &gt;=25%; so median time, 25th and 75th percentiles are not determined.For this reason only the estimated percentage of patient SRE free are reported at each time point.</description>
          <units>Day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">NA=Not evaluable. Due to the low incidence of SRE, K-M estimates never reach a failure probability ≥25%; so median time, 25th and 75th percentiles aren't determined. Time can't be estimated because of insufficient SRE to reach the quartiles</measurement>
                    <measurement group_id="O2" value="NA">NA=Not evaluable. Due to the low incidence of SRE, K-M estimates never reach a failure probability ≥25%; so median time, 25th and 75th percentiles aren't determined. Time can't be estimated because of insufficient SRE to reach the quartiles</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Skeletal Related Event (SRE) Free</title>
        <description>Percentage of participants SRE free is defined as the Kaplan-Meier estimate of participants free of any Skeletal Related Events(SRE) at each time point.
Skeletal Related Events (SREs) are:
pathologic bone fracture; non-vertebral and vertebral
spinal cord compression identified by X-rays
surgery to bone both curative and prophylactic
radiation therapy to bone (palliative, therapeutic or prophylactic)
hypercalcemia of malignancy, defined as a corrected serum calcium &gt; 12 mg/dl (3.00 mmol/l) or a lower level which is symptomatic and requires treatment other than rehydration.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every 3 Months</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid Every 4 Weeks</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Skeletal Related Event (SRE) Free</title>
          <description>Percentage of participants SRE free is defined as the Kaplan-Meier estimate of participants free of any Skeletal Related Events(SRE) at each time point.
Skeletal Related Events (SREs) are:
pathologic bone fracture; non-vertebral and vertebral
spinal cord compression identified by X-rays
surgery to bone both curative and prophylactic
radiation therapy to bone (palliative, therapeutic or prophylactic)
hypercalcemia of malignancy, defined as a corrected serum calcium &gt; 12 mg/dl (3.00 mmol/l) or a lower level which is symptomatic and requires treatment other than rehydration.</description>
          <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="95" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="92" upper_limit="98"/>
                    <measurement group_id="O2" value="97" lower_limit="93" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="90" upper_limit="97"/>
                    <measurement group_id="O2" value="95" lower_limit="91" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="89" upper_limit="96"/>
                    <measurement group_id="O2" value="93" lower_limit="89" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="89" upper_limit="96"/>
                    <measurement group_id="O2" value="92" lower_limit="87" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="83" upper_limit="92"/>
                    <measurement group_id="O2" value="90" lower_limit="85" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="80" upper_limit="90"/>
                    <measurement group_id="O2" value="88" lower_limit="83" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="79" upper_limit="90"/>
                    <measurement group_id="O2" value="85" lower_limit="79" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="78" upper_limit="89"/>
                    <measurement group_id="O2" value="83" lower_limit="77" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="77" upper_limit="88"/>
                    <measurement group_id="O2" value="83" lower_limit="77" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="63" upper_limit="87"/>
                    <measurement group_id="O2" value="82" lower_limit="75" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Bone Pain Score According to the Brief Pain Inventory (BPI) Questionnaire</title>
        <description>Bone pain was assessed by means of a pain score obtained using the Brief Pain Inventory (BPI) questionnaire. The BPI can produce three pain scores: worst pain, a composite pain score, and a pain interference score. The composite pain score, which is the average of questions 3, 4, 5 and 6 of the questionnaire was used in this study. Pain was rated on a scale of 0 (no pain) to 10 (pain as bad as you can imagine). The outcome is given as the median score for participants at baseline, and 3, 6, 9 and 12 months of treatment</description>
        <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
        <population>Intent-to-treat (ITT) population will include all randomized patients. All ITT patients with BPI questionnaire filled up at baseline were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every 3 Months</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid Every 4 Weeks</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Bone Pain Score According to the Brief Pain Inventory (BPI) Questionnaire</title>
          <description>Bone pain was assessed by means of a pain score obtained using the Brief Pain Inventory (BPI) questionnaire. The BPI can produce three pain scores: worst pain, a composite pain score, and a pain interference score. The composite pain score, which is the average of questions 3, 4, 5 and 6 of the questionnaire was used in this study. Pain was rated on a scale of 0 (no pain) to 10 (pain as bad as you can imagine). The outcome is given as the median score for participants at baseline, and 3, 6, 9 and 12 months of treatment</description>
          <population>Intent-to-treat (ITT) population will include all randomized patients. All ITT patients with BPI questionnaire filled up at baseline were included.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N= 186, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.8"/>
                    <measurement group_id="O2" value="2.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N= 156, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.0"/>
                    <measurement group_id="O2" value="2.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N= 143, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.2"/>
                    <measurement group_id="O2" value="1.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N= 131, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.2"/>
                    <measurement group_id="O2" value="2.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N= 135, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.3"/>
                    <measurement group_id="O2" value="2.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pain According to Verbal Rating Scale (VRS) Based on Median Score Value</title>
        <description>Pain intensity at rest and on movement is rated by the patient by means of a validated 6-point Verbal Rating Scale (VRS) and refers to the pain which occurred during the last week before the assessment. Median score value is the median of all the observed scores (none=0, very mild=1, mild=2, moderate=3, severe=5 and very severe=6) at each time point.</description>
        <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
        <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every 3 Months</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid Every 4 Weeks</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pain According to Verbal Rating Scale (VRS) Based on Median Score Value</title>
          <description>Pain intensity at rest and on movement is rated by the patient by means of a validated 6-point Verbal Rating Scale (VRS) and refers to the pain which occurred during the last week before the assessment. Median score value is the median of all the observed scores (none=0, very mild=1, mild=2, moderate=3, severe=5 and very severe=6) at each time point.</description>
          <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Rest: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="1" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Rest: Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2" lower_limit="1.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Rest: Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="1" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Rest: Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="1" lower_limit="1.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Rest: Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="1" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Movement : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="2" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Movement : Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Movement : Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Movement : Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Movement : Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use Of Analgesic Medications According to the Analgesic Score Scale</title>
        <description>The analgesic score used for this study is modified from the Radiation Therapy Oncology Group (RTOG) analgesic score scale. The scale represents type of medication administered from 0 to 4 where:
0 = None
= Minor analgesics (aspirin, NSAID, acetaminophen, propoxyphene, etc.)
= Tranquilisers, antidepressants, muscle relaxants, and steroids
= Mild narcotics (oxycodone, meperidine, codeine, etc.)
= Strong narcotics (morphine, hydromorphone, etc.) The outcome is given a the median score for the participants at Baseline and 3, 6, 9 and 12 months of treatment</description>
        <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
        <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every 3 Months</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid Every 4 Weeks</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Use Of Analgesic Medications According to the Analgesic Score Scale</title>
          <description>The analgesic score used for this study is modified from the Radiation Therapy Oncology Group (RTOG) analgesic score scale. The scale represents type of medication administered from 0 to 4 where:
0 = None
= Minor analgesics (aspirin, NSAID, acetaminophen, propoxyphene, etc.)
= Tranquilisers, antidepressants, muscle relaxants, and steroids
= Mild narcotics (oxycodone, meperidine, codeine, etc.)
= Strong narcotics (morphine, hydromorphone, etc.) The outcome is given a the median score for the participants at Baseline and 3, 6, 9 and 12 months of treatment</description>
          <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of the Eastern Cooperative Oncology Group (ECOG) Performance Score</title>
        <description>ECOG Performance Score has 4 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. Outcome is given as median score for participants at Baseline and 3, 6 , 9 and 12 months of treatment</description>
        <time_frame>At Baseline, Month 3, Month 6, Month 9 and Month 12</time_frame>
        <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every 3 Months</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid Every 4 Weeks</title>
            <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Eastern Cooperative Oncology Group (ECOG) Performance Score</title>
          <description>ECOG Performance Score has 4 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. Outcome is given as median score for participants at Baseline and 3, 6 , 9 and 12 months of treatment</description>
          <population>Intent-to-treat (ITT) population will include all randomized patients.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid Every 3 Months</title>
          <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.</description>
        </group>
        <group group_id="E2">
          <title>Zoledronic Acid Every 4 Weeks</title>
          <description>Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Jaw disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cranial nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Sopor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Breast operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Laparoscopic surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

